Company intelligence / Profile preview

Xiajiang Hemei Pharmaceutical

Jiangxi Sheng, Chinadnb.com ↗

Ownership: Private
Development stage: Commercial

Overview

The lead programs include a HER2 tyrosine kinase inhibitor (sacibertinib) and a TNF-α inhibitor (Hemay007). Clinical development includes Phase 2 activities for immune diseases and Phase 3 for oncology. Clinical trial data focuses on dose-efficacy and safety in ulcerative colitis, and anti-neoplastic indications.

Therapeutic areas: GastroenterologyOncologyImmunology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

lenalidomide

Commercial

Indications: Cancer, Inflammatory diseases

Beyond the preview

Go deeper on Xiajiang Hemei Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xiajiang Hemei Pharmaceutical.

Explore the full profile